• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

胰十二指肠切除术治疗导管腺癌:切缘阳性对生存的影响

Pancreatoduodenectomy for ductal adenocarcinoma: implications of positive margin on survival.

作者信息

Fatima Javairiah, Schnelldorfer Thomas, Barton Joshua, Wood Christina M, Wiste Heather J, Smyrk Thomas C, Zhang Lizhi, Sarr Michael G, Nagorney David M, Farnell Michael B

机构信息

Department of Surgery, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55905, USA.

出版信息

Arch Surg. 2010 Feb;145(2):167-72. doi: 10.1001/archsurg.2009.282.

DOI:10.1001/archsurg.2009.282
PMID:20157085
Abstract

OBJECTIVE

To assess the effect of R0 resection margin status and R0 en bloc resection in pancreatoduodenectomy outcomes.

DESIGN

Retrospective medical record review.

SETTING

Mayo Clinic, Rochester, Minnesota.

PATIENTS

Patients who underwent pancreatoduodenectomy for pancreatic adenocarcinoma at our institution between January 1, 1981, and December 31, 2007, were identified and their medical records were reviewed.

MAIN OUTCOME MEASURE

Median survival times.

RESULTS

A total of 617 patients underwent pancreatoduodenectomy. Median survival times after R0 en bloc resection (n = 411), R0 non-en bloc resection (n = 57), R1 resection (n = 127), and R2 resection (n = 22) were 19, 18, 15, and 10 months, respectively (P < .001). A positive resection margin was associated with death (P = .01). No difference in survival time was found between patients undergoing R0 en bloc and R0 resections after reexcision of an initial positive margin (hazard ratio, 1.19; 95% confidence interval, 0.87-1.64; P = .28).

CONCLUSIONS

R0 resection remains an important prognostic factor. Achieving R0 status by initial en bloc resection or reexcision results in similar long-term survival.

摘要

目的

评估R0切缘状态和R0整块切除对胰十二指肠切除术预后的影响。

设计

回顾性病历审查。

地点

明尼苏达州罗切斯特市梅奥诊所。

患者

确定了1981年1月1日至2007年12月31日期间在本机构接受胰腺癌胰十二指肠切除术的患者,并对其病历进行了审查。

主要观察指标

中位生存时间。

结果

共有617例患者接受了胰十二指肠切除术。R0整块切除(n = 411)、R0非整块切除(n = 57)、R1切除(n = 127)和R2切除(n = 22)后的中位生存时间分别为19个月、18个月、15个月和10个月(P <.001)。切缘阳性与死亡相关(P =.01)。在初次切缘阳性后再次切除的患者中,R0整块切除和R0切除的患者生存时间无差异(风险比,1.19;95%置信区间,0.87 - 1.64;P =.28)。

结论

R0切除仍然是一个重要的预后因素。通过初次整块切除或再次切除达到R0状态可获得相似的长期生存。

相似文献

1
Pancreatoduodenectomy for ductal adenocarcinoma: implications of positive margin on survival.胰十二指肠切除术治疗导管腺癌:切缘阳性对生存的影响
Arch Surg. 2010 Feb;145(2):167-72. doi: 10.1001/archsurg.2009.282.
2
Long-term survival (5-20 years) after pancreatectomy for pancreatic ductal adenocarcinoma: a series of 30 patients collected from 3 institutions.胰十二指肠切除术后胰腺导管腺癌的长期生存(5至20年):来自3家机构收集的30例患者系列研究。
Pancreas. 2008 Nov;37(4):352-7. doi: 10.1097/MPA.0b013e31818166d2.
3
[Results of surgical treatment in ampullary and pancreatic carcinoma and its prognostic parameters after R0-resection].[壶腹癌和胰腺癌的外科治疗结果及其R0切除术后的预后参数]
Zentralbl Chir. 2005 Aug;130(4):353-61. doi: 10.1055/s-2005-836794.
4
Long-term survival after pancreatoduodenectomy for pancreatic adenocarcinoma: is cure possible?胰腺癌胰十二指肠切除术后的长期生存:能否治愈?
Ann Surg. 2008 Mar;247(3):456-62. doi: 10.1097/SLA.0b013e3181613142.
5
Long-term results of partial pancreaticoduodenectomy for ductal adenocarcinoma of the pancreatic head: 25-year experience.胰头导管腺癌行胰十二指肠部分切除术的长期结果:25年经验
World J Surg. 2003 Mar;27(3):324-9. doi: 10.1007/s00268-002-6659-z. Epub 2003 Feb 27.
6
Influence of resection margins and treatment on survival in patients with pancreatic cancer: meta-analysis of randomized controlled trials.切除边缘和治疗对胰腺癌患者生存的影响:随机对照试验的荟萃分析
Arch Surg. 2008 Jan;143(1):75-83; discussion 83. doi: 10.1001/archsurg.2007.17.
7
R1 resection in pancreatic cancer has significant impact on long-term outcome in standardized pathology modified for routine use.R1 切除术在经过标准化病理修正后,对常规使用的胰腺癌的长期预后有显著影响。
Surgery. 2012 Sep;152(3 Suppl 1):S103-11. doi: 10.1016/j.surg.2012.05.015. Epub 2012 Jul 3.
8
Pancreatic resection for M1 pancreatic ductal adenocarcinoma.针对伴有远处转移(M1)的胰腺导管腺癌的胰腺切除术。
Ann Surg Oncol. 2007 Jan;14(1):118-27. doi: 10.1245/s10434-006-9131-8. Epub 2006 Oct 25.
9
Is pancreatectomy with arterial reconstruction a safe and useful procedure for locally advanced pancreatic cancer?胰腺切除术联合动脉重建术对于局部进展期胰腺癌是一种安全且有效的手术吗?
J Hepatobiliary Pancreat Surg. 2009;16(6):850-7. doi: 10.1007/s00534-009-0190-7.
10
Survival after pancreaticoduodenectomy for periampullary adenocarcinoma: an update.壶腹周围腺癌胰十二指肠切除术后的生存情况:最新进展
Eur J Surg Oncol. 2001 Sep;27(6):549-57. doi: 10.1053/ejso.2001.1162.

引用本文的文献

1
Great Debate: Chasing Intraoperative Neck Margins During Pancreatoduodenectomy-Beneficial or Not?大辩论:胰十二指肠切除术中追踪术中颈部切缘——是否有益?
Ann Surg Oncol. 2025 Jun 12. doi: 10.1245/s10434-025-17550-z.
2
Clinical Relevance of High-Grade Pancreatic Intraepithelial Neoplasia at the Pancreatic Transection Margin in Patients with Pancreatic Ductal Adenocarcinoma.胰腺导管腺癌患者胰腺横断缘高级别胰腺上皮内瘤变的临床意义
Ann Surg Oncol. 2025 May 13. doi: 10.1245/s10434-025-17400-y.
3
Personalized three-year survival prediction and prognosis forecast by interpretable machine learning for pancreatic cancer patients: a population-based study and an external validation.
基于可解释机器学习的胰腺癌患者个性化三年生存预测与预后预测:一项基于人群的研究及外部验证
Front Oncol. 2024 Oct 21;14:1488118. doi: 10.3389/fonc.2024.1488118. eCollection 2024.
4
Construction and validation of a nomogram for cancer specific survival of postoperative pancreatic cancer based on the SEER and China database.基于 SEER 和中国数据库的术后胰腺癌特异性生存的列线图构建与验证。
BMC Gastroenterol. 2024 Mar 13;24(1):104. doi: 10.1186/s12876-024-03180-4.
5
Comparison of short-term outcomes of open and laparoscopic assisted pancreaticoduodenectomy for periampullary carcinoma: A propensity score-matched analysis.壶腹周围癌开放与腹腔镜辅助胰十二指肠切除术短期结局的比较:一项倾向评分匹配分析。
Ann Hepatobiliary Pancreat Surg. 2024 May 31;28(2):220-228. doi: 10.14701/ahbps.23-144. Epub 2024 Feb 22.
6
Currently Debated Topics on Surgical Treatment of Pancreatic Ductal Adenocarcinoma: A Narrative Review on Surgical Treatment of Borderline Resectable, Locally Advanced, and Synchronous or Metachronous Oligometastatic Tumor.当前关于胰腺导管腺癌外科治疗的争议话题:关于可切除边缘、局部进展期以及同时性或异时性寡转移瘤外科治疗的叙述性综述
J Clin Med. 2023 Oct 11;12(20):6461. doi: 10.3390/jcm12206461.
7
Practice Patterns and Survival in Patients with Resected Pancreatic Ductal Adenocarcinomas (PDAC) - Results from the Multicentre Indian Pancreatic & Periampullary Adenocarcinoma Project (MIPPAP) Study.切除胰腺导管腺癌(PDAC)患者的治疗模式和生存情况 - 来自多中心印度胰腺和壶腹周围腺癌项目(MIPPAP)研究的结果。
J Gastrointest Cancer. 2023 Dec;54(4):1338-1346. doi: 10.1007/s12029-023-00936-1. Epub 2023 Jun 5.
8
Korean Surgical Practice Guideline for Pancreatic Cancer 2022: A summary of evidence-based surgical approaches.《2022年韩国胰腺癌手术实践指南:基于证据的手术方法总结》
Ann Hepatobiliary Pancreat Surg. 2022 Feb 28;26(1):1-16. doi: 10.14701/ahbps.22-009.
9
Current Limitations and Novel Perspectives in Pancreatic Cancer Treatment.胰腺癌治疗的当前局限与新视角
Cancers (Basel). 2022 Feb 16;14(4):985. doi: 10.3390/cancers14040985.
10
Disparities in pancreatic cancer care and research in Native Americans: Righting a history of wrongs.美国原住民的胰腺癌护理和研究方面的差距:纠正历史上的错误。
Cancer. 2022 Apr 15;128(8):1560-1567. doi: 10.1002/cncr.34118. Epub 2022 Feb 8.